Related Experiment Video
Updated: Sep 10, 2025
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
9.1K
Advances in the Medical Treatment of Clostridioides difficile Infection
Nirja Mehta1, Colleen Kraft2, Stuart Johnson3
1Division of Infectious Diseases, Department of Medicine, Emory University Midtown, 550 Peachtree Avenue NE, Medical Office Tower 7th Floor, Atlanta, GA 30308, USA.
Infectious Disease Clinics of North America
|August 21, 2025
Summary
This review details Clostridioides difficile infection (CDI) management, focusing on preventing recurrence. It compares guidelines for initial, recurrent, and pediatric CDI, and evaluates antibiotic mechanisms and resistance in treatment outcomes.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Clostridioides difficile infection (CDI) management has evolved, with a growing focus on preventing recurrent infections.
- Understanding CDI pathogenesis and antimicrobial resistance is crucial for effective treatment strategies.
Purpose of the Study:
- To compare current guidelines for treating initial, recurrent, fulminant, and pediatric CDI.
- To evaluate the mechanisms of action and clinical utility of available antibiotics for CDI.
- To explore emerging therapies for CDI treatment.
Main Methods:
- Systematic review of current clinical guidelines for CDI treatment.
- Analysis of antibiotic mechanisms of action and resistance patterns in C. difficile.
- Evaluation of the role of novel agents and adjunctive therapies in CDI management.
Main Results:
- Significant changes in CDI management over the last decade, emphasizing recurrence prevention.
- Complex resistance mechanisms to vancomycin, fidaxomicin, and metronidazole identified.
- Tigecycline, rifaximin, and monoclonal antibodies against toxin B show potential as adjunctive therapies.
Conclusions:
- Current CDI treatment guidelines prioritize preventing recurrence.
- Antibiotic resistance poses a challenge, necessitating careful selection of therapies.
- Novel antibiotics and adjunctive treatments offer promising avenues for future CDI management.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
01:17Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202
01:21Inflammatory Bowel Disease V: Surgical Management
212
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
212